Skip to content

Prostate Cancer EMPIRE 2 Findings

September 8, 2026 · 23 min

Show notes

Dr. Ashwin Parihar speaks with Dr. Olayinka A. Abiodun-Ojo and Dr. David M. Schuster about findings from the EMPIRE 2 trial, exploring how fluciclovine PET and PSMA PET influence salvage radiotherapy planning for men with recurrent prostate cancer after prostatectomy. The discussion examines the strengths and limitations of each tracer, the importance of prostate bed detection, and where fluciclovine may still have a role in the evolving era of PSMA-targeted imaging.

18F-Fluciclovine or 68Ga-PSMA-11 PET/CT–guided SalvageRadiotherapy Changes in Postprostatectomy BiochemicalRecurrence: Secondary Analysis of the EMPIRE-2 Trial. Abiodun-Ojo and Jani et al. Radiology 2026; 319(3):e251874.

All episodes of Radiology Podcast | RSNA

Settings

Display

Language

Decides which stations you see first on the home page.

History

Recently played stations and episodes and your latest searches are only stored in this browser.

Notifications

A short notice when a podcast you follow has a new episode. Turn off single podcasts with the bell on their page.

Account

Save favorites – in the app and on the website.

Keyboard shortcuts

/
Open search
Space
Play or pause
← →
In the player: back 15 s, forward 30 s (episodes) · in a row: next tile
↑ ↓
In a row: target within the tile
Home / End
In a row: first or last tile
Esc
Close window or menu
?
This overview
Now playing

Go to station page

Play next

    Add episodes with “Play next” – they play after the current episode.